Physician profile
Ian S Tuznik
NPI 1629310743
$13,402.23
in general payments reported to CMS, 2019-2025
7 companies · $3,922 in 2025
The $3,922 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,697 · 2020: $648 · 2021: $3,348 · 2022: $1,045 · 2023: $1,349 · 2024: $392 · 2025: $3,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,303 · Food and Beverage: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,303.19 |
| Food and Beverage | $2,359.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $4,388.42 | 2019-2025 | Persona, Rosa, G7 |
| Stryker Corporation | $3,888.58 | 2019-2025 | Mako, Insignia, Salvation |
| Sequoia Surgical, INC. | $3,040.83 | 2020-2021 | |
| Medacta USA, INC. | $1,935.86 | 2025 | Gmk Sphere, Spherika |
| Biotissue Holdings INC. | $98.36 | 2024 | |
| Depuy Synthes Sales INC. | $33.22 | 2024 | Na, Tfn-Advance |
| Cornerstone Medical Associates, INC. | $16.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Tuznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.